FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer-Reference-Cited by-同舟云学术

FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer

Published:2015-08 Issue:2 Volume:89 Page:115-120
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Kohutek Zachary A.,Wu Abraham J.,Zhang Zhigang,Foster Amanda,Din Shaun U.,Yorke Ellen D.,Downey Robert,Rosenzweig Kenneth E.,Weber Wolfgang A.,Rimner Andreas

Funder

NIH

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis;Palma;J Clin Oncol,2010

2. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis;Senthi;Lancet Oncol,2012

3. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer;Grills;J Clin Oncol,2010

4. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant;Bradley;Int J Radiat Oncol Biol Phys,2010

5. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules;Khalaf;J Hematol Oncol,2008

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations;Frontiers in Immunology;2024-05-07

2. Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments;Thoracic Cancer;2024-04

3. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation;Radiotherapy and Oncology;2024-01

4. Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy;Advances in Radiation Oncology;2024-01

5. Influence de l’immunothérapie sur le choix du traitement des cancers bronchiques non à petites cellules de stade I : point de vue de l’oncologue radiothérapeute;Cancer/Radiothérapie;2023-09